We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diabetes Diagnosed by Breath Analysis

By LabMedica International staff writers
Posted on 12 Jan 2011
A unique technology enables rapid, accurate, and low-cost diagnostics for diabetes through breath analysis.

Using the Oxford Medical Diagnostics (OMD; Oxford, UK) proprietary Cavity Enhanced Absorption Spectroscopy (CEAS) and Plasma Emission Spectroscopy (PES) technologies, the company team is developing advanced methods of convenient and noninvasive breath analysis targeted at the detection of metabolic and infectious diseases. More...
OMD is currently prototyping a noninvasive point-of-care diagnostic instrument to detect diabetes types 1 and 2, by identifying acetone in the breath.

Currently, there is a significant inadequacy of diabetes testing methods. The Oxford Medical Diagnostics technology and expertise has further significant applications in both medicine and industry, including the automated detection of bacterial species such as methicillin resistant Staphylococcus aureus (MRSA) and Clostridium difficile, and the diagnosis of lung cancer and asthma. Acetone in breath is also a definitive marker of fat-burning weight loss, athletic metabolic performance, as well as certain eating disorders

The company is considered to be one of the most successful entities linked to the University of Oxford and its Intellectual Property (IP) company Isis Innovation.

Related Links:

Oxford Medical Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.